Maraviroc reduced intratumoral type I collagen- or α-SMA-positive fibroblast areas with few effects on CD31-positive areas (Figure 4D) or on Ly6G-positive granulocyte and F4/80-positive macrophage percentages in the tumor sites (data not shown). Here, ACTA1 is linked to neoplasm.